BACKGROUND: Tumor protein 53 (TP53) mutations are uncommon in adult patients with acute lymphoblastic leukemia (ALL) and predict a poor outcome. METHODS: TP53 mutation analysis was performed in 164 newly diagnosed adult patients with ALL using a combination of targeted amplicon-based next-generation sequencing and Sanger sequencing. RESULTS: TP53 mutations were detected in 25 patients (15%), with a median allelic frequency of 42.2% (range, 5.6%-93.8%). The majority of mutations were singlenucleotide variants of missense type and involved the DNA-binding domain. TP53-mutated (TP53 mut ) ALL was found to be significantly associated with older age, lower median white blood cell and platelet counts, lower frequency of Philadelphia chromosome and a higher frequency of low hypodiploid karyotype compared with ALL with wild-type TP53 (TP53 wt ). To evaluate the prognostic effect of TP53 mutations, the authors selected 146 patients with B-cell immunophenotype ALL (24 with TP53 mut and 122 with TP53 wt )
INTRODUCTION
The tumor protein 53 (TP53) gene plays a significant role in maintaining genomic stability in response to DNA damage by activating DNA repair programs and triggering cell-cycle arrest.
1,2 TP53 gene mutations (TP53 mut ) have been reported to be associated with refractoriness to chemotherapy and higher rates of disease recurrence in pediatric patients with acute lymphoblastic leukemia (ALL), similar to other malignancies. [3] [4] [5] The limited studies available regarding TP53 mut in newly diagnosed adult ALL patients have reported variable mutation frequencies, ranging between 6% and 19%, [6] [7] [8] [9] with significant enrichment within B-cell immunophenotype ALL (B-ALL) with absent Philadelphia chromosome (Ph). 6, 10 These studies suggest that patients with TP53 mut ALL have an inferior overall survival (OS), 6 a poor response to induction, 7 and a higher propensity of disease recurrence 8 compared with patients with wild-type TP53 (TP53 wt ) ALL. However, to the best of our knowledge, the majority of these studies analyzed patient cohorts that were heterogeneous with respect to age, treatment, and MYC rearrangement.
In the current study, we report the clinical characteristics and impact of TP53 mutations on survival outcomes among patients with adult ALL who were treated with frontline hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD)-based regimens at a single institution.
MATERIALS AND METHODS

Study Group
We conducted a retrospective review of all consecutive adults (aged >18 years) with newly diagnosed ALL who were treated with hyper-CVAD-based regimens (111 patients were enrolled on clinical trials and 35 were treated off clinical trials) at The University of Texas MD Anderson Cancer Center in Houston between 2012 and 2016 and who underwent testing for the TP53 mutation. Patients with Burkitt/MYC-positive ALL were excluded. The study was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center; informed consent was obtained from all patients.
Response and Outcome Definitions
Complete remission (CR) was defined as the 1) <5% blasts in the bone marrow aspirate; 2) a neutrophil count >1310 9 /L and a platelet count >100310 9 /L in the peripheral blood; and 3) no evidence of extramedullary disease. Disease relapse was defined as the recurrence of 5% blasts in the bone marrow aspirate or the detection of extramedullary disease.
Cytogenetic Studies
Conventional cytogenetic studies were performed on pretreatment bone marrow specimens using standard techniques. Karyotypic results were reported using the 2013 International System for Human Cytogenetic Nomenclature. 11 Karyotypes were classified into cytogenetic categories as described elsewhere. 12, 13 A complex karyotype was defined as 5 chromosomal abnormalities excluding those patients with an established recurrent translocation or low hypodiploidy/near triploidy, hyperdiploidy, or tetraploidy. Fluorescence in situ hybridization (FISH) studies for TP53 gene deletion was performed on bone marrow aspirate smears or bone marrow cultured cells using a LSI TP53/CEP 17 dual-color probe (Abbott Molecular Inc, Abbott Park, Illinois). BCR-ABL1 rearrangement was tested by FISH using the LSI BCR/ABL1 dual-color, translocation ES probe (Abbott Molecular Inc). A total of 200 interphases were analyzed. Positive cutoff values of 4.7% for TP53 deletion and 0% (minor break-apart pattern) or 2% (major break-apart pattern) for BCR/ABL1 rearrangement were established in the study cytogenetic laboratory.
Molecular Analysis
TP53 mutation analysis was assessed on bone marrow samples by targeted next-generation sequencing (NGS)-based multigene profiling 14 Single-nucleotide polymorphisms (SNPs) listed in the SNP database (dbSNP) 137 and dbSNP 138 and the Genome 10K Project were excluded. TP53 mutation analysis within exons 4 through 9 using Sanger sequencing was performed after polymerase chain reaction using standard techniques (sensitivity of 10%-20%).
Assessment of Minimal Residual Disease
For patients with Ph-positive ALL, assessment of minimal residual disease (MRD) was performed using reverse transcriptase-polymerase chain reaction. 15 For patients with Ph-negative ALL, MRD was assessed using 6-color multiparametric flow cytometry analysis. 16 
Statistical Analysis
Comparisons between categorical and continuous variables between the TP53 mut and TP53 wt groups were performed using the Fisher exact test and Student t test for paired data, respectively. OS was calculated from the time of treatment initiation to death; event-free survival (EFS) was calculated from the time of treatment initiation to disease recurrence, disease progression, or death. The median OS and EFS were estimated using Kaplan-Meier analysis (GraphPad Prism software; GraphPad Software, San Diego, California). Outcome differences between the groups were assessed using the log-rank test. The associations between survival outcome and different parameters were determined with Cox proportional hazards regression models using SPSS statistical software (version 22; IBM Corporation, Armonk, NY). A P value .05 was considered to be statistically significant.
RESULTS
Patient Characteristics
In total, 164 adult patients with ALL who underwent treatment with hyper-CVAD regimens with available TP53 mutation status were identified in our database. These included 97 men and 67 women with a median age at the time of presentation of 53 years (range, 18-81 years). The majority of patients (146 patients; 89%) had B-ALL, whereas only 18 patients had ALL of T-cell immunophenotype (T-ALL). Within the B-ALL patient group, complete karyotype and flow immunophenotypic data were available for 139 patients; classification using the 2016 World Health Organization classification demonstrated 59 patients (40.4%) with B-lymphoblastic leukemia/lymphoma with t(9;22); 5 patients (3.4%) with t(v;11q23.3); 6 patients (4.1%) with hyperdiploidy; 13 patients (8.9%) with hypodiploidy (12 of whom met the criteria for the low hypodiploid karyotype, defined as 30-39 chromosomes); 3 patients (2.1%) with t(1;19); and 53 patients (36.3%) with B-lymphoblastic leukemia/lymphoma, not otherwise specified. Eleven patients demonstrated the early precursor B-ALL immunophenotype, 81 patients demonstrated common B-ALL, and 47 patients demonstrated the precursor B-ALL immunophenotype.
Of the total of 164 patients, 25 patients had a TP53 mutation. Of these 25 patients, 24 with TP53 mut ALL (96%) were of B-cell type. The clinical, laboratory, and cytogenetic characteristics of the TP53 mut and TP53 wt ALL subgroups are presented in Table 1. Compared with  patients with TP53 wt ALL, patients with TP53 mut ALL were found to be significantly older at the time of presentation (median age, 64 years vs 47 years; P 5 .007), and had a significantly lower median white blood cell count (2.0K/lL vs 5.0K/lL; P 5 .009) and a lower median platelet count (22K/lL vs 40K/lL; P 5 .02). Patients with TP53 mut ALL had a lower frequency of Ph (4% vs 42%; P 5 .0002) and a higher frequency of low hypodiploidy (44% vs 1%; P 5 .0001). The distribution of complex karyotype did not differ significantly between the 2 groups (P 5 .3).
TP53 Mutation Characteristics
A total of 29 TP53 mutations were identified in 25 of 164 patients (15%); 2 patients had 2 concomitant TP53 mutations each and 1 patient had 3 TP53 mutations. These included 28 point mutations (97%) (25 missense and 3 nonsense mutations) and 1 frameshift duplication. A total of 27 mutations (93%) involved the DNA-binding domain (Fig. 1A) . All missense mutations were predicted to be nonfunctional for transcriptional activity and deleterious as per the scale-invariant feature transform (SIFT) algorithm. 17 The most common amino acid change (13 of 29 mutations) involved substitution of arginine residues. For 22 of 25 patients with TP53 mut ALL identified by NGS, the median mutant allelic frequency (MAF) was Figure 1B .
TP53 Gene Deletion
Within the cohort of patients with TP53 mut ALL, we assessed for the copy number state of the TP53 gene. Eleven of 25 patients with TP53 mut ALL (10 with B-ALL and 1 with T-ALL) demonstrated monosomy 17 by karyotype. In the remaining 14 patients without chromosome 17 abnormalities, interphase FISH was successful in 5 patients, 3 of whom demonstrated both TP53 and CEP17 deletions (monosomy 17). In total, 14 patients with TP53 mut ALL were found to have both a mutation and deletion and 2 patients had a TP53 mutation without deletion, whereas the copy number state of the TP53 gene could not be determined in 9 patients.
Survival Outcome
To assess the prognostic impact of TP53 mut in a homogeneous population, we excluded the 18 patients with T-ALL. The final cohort for survival analysis included 24 patients with TP53 mut and 122 patients with TP53 wt B-ALL. All patients were treated with frontline hyper-CVAD or mini-hyperfractionated cyclophosphamide, vincristine, and dexamethasone-based regimens. [18] [19] [20] [21] [22] Treatment details and outcomes are presented in Tables 2  and 3 . The median duration of follow-up was 15 months (range, 0.2-41 months); there was no significant difference in survival rates noted between patients with 
TP53
mut and TP53 wt ALL ( Figs. 2A and 2B ). For patients with TP53 mut and TP53 wt disease, the 3-year OS rates were 55% and 59%, respectively (P 5 .49), and the 3-year EFS rates were 53% and 50%, respectively (P 5 .66). There was no significant difference with regard to OS or EFS rates noted between patients with TP53 mut and TP53
wt ALL when only patients with Ph-negative B-ALL were assessed (3-year OS rates: 51% and 43%
[P 5 .6]; and 3-year EFS rates: 50% and 48% [P 5 .68]). It is interesting to note that the OS and EFS survival curves for patients with TP53
mut and TP53 wt ALL demonstrated a tendency to diverge between 10 and 20 months of follow-up. However, no common cause of death was identified in patients with TP53 mut ALL during this time period (sepsis in 2 patients, post-stem cell transplantation complications in 1 patient, and encephalitis in 1 patient). The duration of CR was found to be similar between patients with TP53 mut and TP53 wt ALL (patients with B-ALL and Ph-negative B-ALL) (Figs. 2C and 2D ). There was no significant difference noted with regard to the CR rates (83% in patients with TP53 mut ALL vs 91% in patients with TP53 wt ALL; P 5 .25) or MRD negativity rates at CR (67% in patients with TP53 mut ALL vs 59% in patients with TP53 wt ALL; P 5 .48). Although patients with low hypodiploidy had a trend toward an inferior outcome, there were no statistically significant differences noted with regard to EFS, OS, or CR duration between patients with ALL with low hypodiploid and diploid karyotypes (OS: 27.5 months vs undefined [P 5
.73]; and EFS: 18 months vs 27.5 months [P 5 .82]). Similarly, within the TP53 mut subgroup, there were no statistically significant differences with regard to EFS or OS noted between patients with low hypodiploid (11 patients) and diploid (5 patients) karyotypes (P 5 .79 for EFS and P 5 .62 for OS). Furthermore, we assessed outcome by whether patients with TP53 mut B-ALL had gene deletion (13 patients) or not (2 patients); patients with TP53 mut B-ALL with TP53 gene deletion were found to have a worse OS (27.5 months vs unreached; P 5 .2) and EFS (18 months vs unreached; P 5 .1) compared with patients with TP53 mut B-ALL without gene deletion. This difference was not significant due to the limited number of patients. In addition, comparison of OS and EFS between patients with homozygous and heterozygous/subclonal TP53 mut did not demonstrate a significant difference, although the current study was limited in number. Assessment of OS, EFS, and duration of CR in patients with 
DISCUSSION
The results of the current study demonstrate that TP53 mut is encountered in approximately 15% of adults with newly diagnosed ALL, with a significant association with the low hypodiploid karyotype. The current study data also confirmed previously published findings [6] [7] [8] that TP53 mutations predominantly occur in older patients with B-ALL with a low frequency of Ph. However, in contrast with 3 previous studies that have analyzed the impact of TP53 mutations in newly diagnosed adult patients with ALL, 6-8 the current study did not observe any significant difference in survival and CR duration between patients with TP53 mut and TP53 wt B-ALL. Chiaretti et al 7 evaluated 98 heterogeneously treated adult patients with ALL, and demonstrated a poorer response to induction therapy in those with TP53 mut ALL. Their TP53 mut frequency was lower (6%), which most likely is attributable to the lower median age and the use of a less sensitive microarray-based mutation assay compared with deep sequencing. Stengel et al 6 demonstrated that patients with TP53 mut ALL had a shorter survival, especially when the disease was associated with wild-type TP53 allele loss. Their cohort included a mixture of patients with adult, childhood, and Burkitt/MYC-positive ALL. It is important to note that neither study analyzed the impact of TP53 mutations in uniformly treated patients, which may have confounded the results. Recently, Salmoiraghi et al 8 evaluated 171 patients with Ph-negative ALL who were treated on the NILG-ALL (Northern Italy Leukemia Group-Acute Lymphoblastic Leukemia) 09/2000 clinical trial. TP53 mutation was found to be independently associated with a worse OS and a higher cumulative incidence of disease recurrence. However, the incidence of TP53 mutations (approximately 8%) was lower (in the current study, the frequency of TP53 mut in patients with Ph-negative ALL was 23%), most likely due to the lower median age of the patients. To the best of our knowledge, in all these studies, it is unclear whether the poor outcomes in patients with TP53 mut ALL were due to the TP53 mutations themselves or to the overlap with low hypodiploidy, which is an independent predictor of worse OS and recurrence-free survival by itself. 12 In contrast to European studies, the patients in the current study were treated with hyper-CVAD-based regimens in combination with newer targeted therapies such as anti-CD20/anti-CD22 monoclonal antibodies and tyrosine kinase inhibitors (in patients with Ph-positive ALL). 21, 23 Prior studies have shown a survival benefit with the addition of rituximab to standard chemotherapy for adults with CD20-positive ALL. 19, 24 Similarly, in one study, the addition of inotuzumab ozogamicin to the mini-hyperfractionated cyclophosphamide, vincristine, and dexamethasone regimen in older adults was associated with excellent outcomes that were significantly improved compared with a historical cohort of patients who did not receive inotuzumab ozogamicin. 20 The incorporation of tyrosine kinase inhibitors into regimens for patients with Ph-positive ALL also has significantly improved outcomes in this subset of patients with ALL. 23 In the current study, approximately 91% of all patients with ALL (87.5% of patients with TP53 mut ALL) received a monoclonal antibody as part of the induction and consolidation regimen. The finding that TP53 mut does not confer a negative prognosis in patients treated predominantly with regimens incorporating monoclonal antibodies suggests that chemoimmunotherapy may be able to overcome the poor prognostic effect of TP53 mut in patients with B-ALL. In the current study, neither TP53 mutation status nor hypodiploid karyotype was found to be associated with an adverse outcome. A previously published study from our group demonstrated that low hypodiploidy/ near-triploidy was an independent predictor of worse OS and recurrence-free survival in patients with Ph-negative ALL. 12 The cohort in the current study was different with the exception of 3 patients, because the selection criteria included patients with known TP53 mutation status; those with low hypodiploid karyotype had an inferior OS compared with those with the diploid karyotype, but this difference was not statistically significant. The current study is limited by the small number of patients with TP53 mutations and a relatively shorter duration of follow-up. Stengel et al have demonstrated that the presence of TP53 mutations and deletions had a significantly negative impact on the OS of patients with ALL, whereas TP53 mutations alone did not. 9 In the current study, patients with TP53 mut B-ALL with a TP53 deletion demonstrated a shorter OS and EFS compared with patients with TP53 mut B-ALL without a TP53 gene deletion. However, these findings were not statistically significant due to the small number of patients with TP53 mut B-ALL in the current study. Furthermore, due to the limited availability of genomic DNA, SNP-based microarrays could not be performed retrospectively. Therefore, copyneutral loss of heterozygosity of the TP53 gene could not be assessed. Comprehensive genomic profiling that includes the assessment of gene mutations and deletions on a larger scale is warranted for definitive conclusions. A further limitation of the current study is that a subset of patients with TP53 wt who were tested by Sanger sequencing may indeed have had the mutation at a low level or outside of tested exons. However, this is likely to be the case for very few patients, because the median bone marrow blast percentage of those patients tested using Sanger sequencing was 81%. Furthermore, among the 22 TP53 mutations detected by NGS, only 1 (approximately 5%) was located outside of exons 4 to 9.
The results of the current study demonstrate that TP53 mutations may not have a significant negative impact on survival in adult patients with newly diagnosed ALL after frontline treatment with hyper-CVAD-based regimens. Further studies currently are underway to expand the cohort and to identify the relevance of TP53 mutations in the era of novel chemoimmunotherapies.
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